Disturbances of volume-regulating peptides like vasopressin (AVP) and atrial natriuretic peptide (ANP) have been described in early abstinent alcohol-dependent patients. In a longitudinal approach, we investigated whether changes in AVP and ANP serum levels correlated to cytosine-phosphatidyl-guanine (CpG) methylation of the respective gene promoters on days 1, 7 and 14 of alcohol withdrawal. We analyzed the blood samples of 99 patients suffering from alcohol dependence alongside age- and BMI-matched controls. Concerning AVP promoter methylation, we observed an interaction between time of measurement and CpG loci with CpG 2 showing a significant increase in methylation from day 1 to 14. Serum levels of AVP were significantly decreased in the patient group. Compared to healthy controls, promoter-related DNA methylation of the ANP promoter was significantly reduced on days 7 and 14. Moreover, we detected a significant interaction between CpG position and group. In both cases the difference was mainly observed at CpG 1. The present study shows significant changes in the methylation status of individual CpG sites of AVP and ANP. Observing respective alterations of AVP serum protein levels in alcohol-dependent patients during detoxification treatment, we consider methylation as a possible mode of regulation for these proteins during alcohol detoxification.

1.
Kohler S, Klimke S, Hellweg R, Lang UE: Serum brain-derived neurotrophic factor and nerve growth factor concentrations change after alcohol withdrawal: preliminary data of a case-control comparison. Eur Addict Res 2013;19:98-104.
2.
Hillemacher T, Bayerlein K, Wilhelm J, Poleo D, Frieling H, Ziegenbein M, Sperling W, Kornhuber J, Bleich S: Volume intake and craving in alcohol withdrawal. Alcohol Alcohol 2006;41:61-65.
3.
Hillemacher T, Frieling H, Luber K, Yazici A, Muschler MA, Lenz B, Wilhelm J, Kornhuber J, Bleich S: Epigenetic regulation and gene expression of vasopressin and atrial natriuretic peptide in alcohol withdrawal. Psychoneuroendocrinology 2009;34:555-560.
4.
Kiefer F, Andersohn F, Jahn H, Wolf K, Raedler TJ, Wiedemann K: Involvement of plasma atrial natriuretic peptide in protracted alcohol withdrawal. Acta Psychiatr Scand 2002;105:65-70.
5.
Döring WK, Herzenstiel MN, Krampe H, Jahn H, Pralle L, Sieg S, Wegerle E, Poser W, Ehrenreich H: Persistent alterations of vasopressin and N-terminal proatrial natriuretic peptide plasma levels in long-term abstinent alcoholics. Alcohol Clin Exp Res 2003;27:849-861.
6.
Strohle A, Feller C, Strasburger CJ, Heinz A, Dimeo F: Anxiety modulation by the heart? Aerobic exercise and atrial natriuretic peptide. Psychoneuroendocrinology 2006;31:1127-1130.
7.
Wiedemann K, Jahn H, Yassouridis A, Kellner M: Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings. Arch Gen Psychiatry 2001;58:371-377.
8.
Antoni FA, Hunter EF, Lowry PJ, Noble JM, Seckl JR: Atriopeptin: an endogenous corticotropin-release inhibiting hormone. Endocrinology 1992;130:1753-1755.
9.
Laczi F, Valkusz Z, Laszlo FA, Wagner A, Jardanhazy T, Szasz A, Szilard J, Telegdy G: Effects of lysine-vasopressin and 1-deamino-8-D-arginine-vasopressin on memory in healthy individuals and diabetes insipidus patients. Psychoneuroendocrinology 1982;7:185-193.
10.
Landgraf R: Neuropeptides in anxiety modulation. Handb Exp Pharmacol 2005;169:335-369.
11.
Mazzocchi G, Malendowicz LK, Rebuffat P, Tortorella C, Nussdorfer GG: Arginine-vasopressin stimulates CRH and ACTH release by rat adrenal medulla, acting via the V1 receptor subtype and a protein kinase C-dependent pathway. Peptides 1997;18:191-195.
12.
Kaye WH, Weltzin TE: Neurochemistry of bulimia nervosa. J Clin Psychiatry 1991;52(suppl):21-28.
13.
Keck ME: Corticotropin-releasing factor, vasopressin and receptor systems in depression and anxiety. Amino Acids 2006;31:241-250.
14.
Surget A, Belzung C: Involvement of vasopressin in affective disorders. Eur J Pharmacol 2008;583:340-349.
15.
Zelena D: Vasopressin in health and disease with a focus on affective disorders. Cent Nerv Syst Agents Med Chem 2012;12:286-303.
16.
Hillemacher T, Kahl KG, Heberlein A, Muschler MA, Eberlein C, Frieling H, Bleich S: Appetite- and volume-regulating neuropeptides: role in treating alcohol dependence. Curr Opin Investig Drugs 2010;11:1097-1106.
17.
Mutschler J, Bilbao A, von der Goltz C, Demiralay C, Jahn H, Wiedemann K, Spanagel R, Kiefer F: Augmented stress-induced alcohol drinking and withdrawal in mice lacking functional natriuretic peptide-A receptors. Alcohol Alcohol 2010;45:13-16.
18.
Ruskoaho H: Atrial natriuretic peptide: synthesis, release, and metabolism. Pharmacol Rev 1992;44:479-602.
19.
Rodenhiser D, Mann M: Epigenetics and human disease: translating basic biology into clinical applications. CMAJ 2006;174:341-348.
20.
Auger CJ, Coss D, Auger AP, Forbes-Lorman RM: Epigenetic control of vasopressin expression is maintained by steroid hormones in the adult male rat brain. Proc Natl Acad Sci USA 2011;108:4242-4247.
21.
Bonsch D, Greifenberg V, Bayerlein K, Biermann T, Reulbach U, Hillemacher T, Kornhuber J, Bleich S: Alpha-synuclein protein levels are increased in alcoholic patients and are linked to craving. Alcohol Clin Exp Res 2005;29:763-765.
22.
Bleich S, Lenz B, Ziegenbein M, Beutler S, Frieling H, Kornhuber J, Bonsch D: Epigenetic DNA hypermethylation of the HERP gene promoter induces down-regulation of its mRNA expression in patients with alcohol dependence. Alcohol Clin Exp Res 2006;30:587-591.
23.
Harding AJ, Halliday GM, Ng JL, Harper CG, Kril JJ: Loss of vasopressin-immunoreactive neurons in alcoholics is dose-related and time-dependent. Neuroscience 1996;72:699-708.
24.
Madeira MD, Sousa N, Lieberman AR, Paula-Barbosa MM: Effects of chronic alcohol consumption and of dehydration on the supraoptic nucleus of adult male and female rats. Neuroscience 1993;56:657-672.
25.
Paula-Barbosa MM, Silva SM, Andrade JP, Cadete-Leite A, Madeira MD: Nerve growth factor restores mRNA levels and the expression of neuropeptides in the suprachiasmatic nucleus of rats submitted to chronic ethanol treatment and withdrawal. J Neurocytol 2001;30:195-207.
26.
Silva SM, Paula-Barbosa MM, Madeira MD: Prolonged alcohol intake leads to reversible depression of corticotropin-releasing hormone and vasopressin immunoreactivity and mRNA levels in the parvocellular neurons of the paraventricular nucleus. Brain Res 2002;954:82-93.
27.
Sousa N, Madeira MD, Ruela C, Paula-Barbosa MM: Structural reorganization in the supraoptic nucleus of withdrawn rats following long-term alcohol consumption. Alcohol Clin Exp Res 1995;19:879-885.
28.
De Vries GJ, Buijs RM: The origin of the vasopressinergic and oxytocinergic innervation of the rat brain with special reference to the lateral septum. Brain Res 1983;273:307-317.
29.
de Bold AJ: Atrial natriuretic factor: a hormone produced by the heart. Science 1985;230:767-770.
30.
Wiedemann K, Jahn H, Kellner M: Effects of natriuretic peptides upon hypothalamo-pituitary-adrenocortical system activity and anxiety behaviour. Exp Clin Endocrinol Diabetes 2000;108:5-13.
31.
Kellner M, Jahn H, Wiedemann K: Natriuretic peptides and panic disorder: therapeutic prospects. Expert Rev Neurother 2003;3:381-386.
32.
Kiefer F, Witt SH, Frank J, Richter A, Treutlein J, Lemenager T, Nothen MM, Cichon S, Batra A, Berner M, Wodarz N, Zimmermann US, Spanagel R, Wiedemann K, Smolka MN, Heinz A, Rietschel M, Mann K: Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate. Pharmacogenomics J 2011;11:368-374.
33.
Ito S, Ohtsuki S, Katsukura Y, Funaki M, Koitabashi Y, Sugino A, Murata S, Terasaki T: Atrial natriuretic peptide is eliminated from the brain by natriuretic peptide receptor-C-mediated brain-to-blood efflux transport at the blood-brain barrier. J Cereb Blood Flow Metab 2011;31:457-466.
34.
Davies MN, Volta M, Pidsley R, Lunnon K, Dixit A, Lovestone S, Coarfa C, Harris RA, Milosavljevic A, Troakes C, Al-Sarraj S, Dobson R, Schalkwyk LC, Mill J: Functional annotation of the human brain methylome identifies tissue-specific epigenetic variation across brain and blood. Genome Biol 2012;13:R43.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.